Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia - PubMed (original) (raw)
. 2006 Jun;91(6):2055-61.
doi: 10.1210/jc.2005-2105. Epub 2006 Mar 21.
Munro Peacock, Pisit Pitukcheewanont, Howard J Heller, Leanne M Ward, Dorothy Shulman, Moustapha Kassem, Paula Rackoff, Mark Zimering, Alan Dalkin, Elaine Drobny, Giacomo Colussi, Joseph L Shaker, Elizabeth H Hoogendoorn, Siu L Hui, Michael J Econs
Affiliations
- PMID: 16551733
- DOI: 10.1210/jc.2005-2105
Free article
Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia
Erik A Imel et al. J Clin Endocrinol Metab. 2006 Jun.
Free article
Abstract
Context: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome of hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum 1,25-dihydryxyvitamin-D concentration, myopathy, and osteomalacia. Fibroblast growth factor 23 (FGF23) is a phosphaturic protein overexpressed in tumors that cause TIO and is, at least partly, responsible for the manifestations of TIO.
Objective: The objective of this study was to determine the sensitivity of FGF23 measurements in TIO.
Design: FGF23 concentrations were measured on stored samples with three ELISAs.
Setting: This study was conducted at subspecialty referral centers.
Patients: Twenty-two patients with suspected TIO, 13 with confirmed tumors, were studied.
Interventions: There were no interventions in this study.
Main outcome measure: FGF23 concentration was the main outcome measure of this study.
Results: Elevated FGF23 concentrations were detected using the Immunotopics C-terminal assay in 16 of 22 TIO patients (for a sensitivity of 73%), the Immunotopics Intact assay in five of 22 patients (sensitivity, 23%), and the Kainos Intact assay in 19 of 22 patients (sensitivity, 86%). In the 13 patients with confirmed tumors, the sensitivity was higher with all assays: 92% for the Immunotopics C-terminal assay, 38% for the Immunotopics Intact assay, and 100% for the Kainos assay.
Conclusion: The Kainos Intact assay was the most sensitive, followed by the Immunotopics C-terminal assay. The findings of normal FGF23 concentrations in some patients with TIO may indicate that FGF 23 is not responsible for the hypophosphatemia in these patients or that FGF23 secretion by some tumors is partially responsive to serum phosphate. Normal FGF23 concentrations should be interpreted in relation to the serum phosphate and 1,25-dihydryxyvitamin-D concentrations.
Similar articles
- A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R, Onodera T, Terkawi MA, Mitsuhashi T, Kondo E, Iwasaki N. Arai R, et al. BMC Musculoskelet Disord. 2017 Feb 13;18(1):79. doi: 10.1186/s12891-017-1446-z. BMC Musculoskelet Disord. 2017. PMID: 28193220 Free PMC article. - Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H. Jonsson KB, et al. N Engl J Med. 2003 Apr 24;348(17):1656-63. doi: 10.1056/NEJMoa020881. N Engl J Med. 2003. PMID: 12711740 - Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T. Endo I, et al. Bone. 2008 Jun;42(6):1235-9. doi: 10.1016/j.bone.2008.02.014. Epub 2008 Mar 5. Bone. 2008. PMID: 18396126 - Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.
Hu FK, Yuan F, Jiang CY, Lv DW, Mao BB, Zhang Q, Yuan ZQ, Wang Y. Hu FK, et al. Chin J Cancer. 2011 Nov;30(11):794-804. doi: 10.5732/cjc.011.10013. Chin J Cancer. 2011. PMID: 22035861 Free PMC article. Review.
Cited by
- The Intricacies of Renal Phosphate Reabsorption-An Overview.
Walker V. Walker V. Int J Mol Sci. 2024 Apr 25;25(9):4684. doi: 10.3390/ijms25094684. Int J Mol Sci. 2024. PMID: 38731904 Free PMC article. Review. - [Value of serum fibroblast growth factor 23 in diagnosis of hypophosphatemic rickets in children].
Dong SS, Che RC, Zheng BX, Zhang AH, Wang CL, Bai M, Chen Y. Dong SS, et al. Zhongguo Dang Dai Er Ke Za Zhi. 2023 Jul 15;25(7):705-710. doi: 10.7499/j.issn.1008-8830.2303016. Zhongguo Dang Dai Er Ke Za Zhi. 2023. PMID: 37529952 Free PMC article. Chinese. - Co-occurrence of Spondyloepiphyseal Dysplasia and X-Linked Hypophosphatemia in a Three-Generation Chinese Family.
Ma J, Zhang Y, Ding X, Liang Z, Yang C, Deng Z, He H, Guan Z, Zeng C, Lin Y, Luo X. Ma J, et al. Calcif Tissue Int. 2023 Sep;113(3):266-275. doi: 10.1007/s00223-023-01104-0. Epub 2023 Jun 6. Calcif Tissue Int. 2023. PMID: 37278761 Free PMC article. - Fibroblast growth factor 23 in children with or without heart failure: a prospective study.
Elzayat RS, Bahbah WA, Elzaiat RS, Elgazzar BA. Elzayat RS, et al. BMJ Paediatr Open. 2023 Feb;7(1):e001753. doi: 10.1136/bmjpo-2022-001753. BMJ Paediatr Open. 2023. PMID: 36828640 Free PMC article. - Biomarkers of Vitamin D Metabolism and Hip and Vertebral Fracture Risk: The Multi-Ethnic Study of Atherosclerosis.
Hsu S, Criqui MH, Ginsberg C, Hoofnagle AN, Ix JH, McClelland RL, Michos ED, Shea SJ, Siscovick D, Zelnick LR, Kestenbaum BR, de Boer IH. Hsu S, et al. JBMR Plus. 2022 Nov 11;6(12):e10697. doi: 10.1002/jbm4.10697. eCollection 2022 Dec. JBMR Plus. 2022. PMID: 36530185 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources